Perspective Therapeutics, Inc. (CATX)

ASE – Цена в реальном времени. Валюта: USD

3.77

-0.11 (-2.84%)

При закрытии: May 12, 2026, 4:00 PM EDT

3.79

+0.02 (0.53%)

После закрытия: May 12, 2026, 7:39 PM EDT

27.04.2026

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics (CATX) is advancing radiopharmaceutical therapies, with a pivotal data readouts expected in 2026 in NETs, plus melanoma / solid tumor data. CATX's VMT-α-NET shows promising early efficacy in SSTR2-positive neuroendocrine tumors, with 76% of patients alive and progression-free in a 25-patient study. Sanofi's discontinuation of Alphamedix and promising comparison withy Novartis' Lutathera highlight significant market opportunity for CATX's pipeline.

24.04.2026

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

SEATTLE, April 24, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will provide several corporate updates in May 2026. Webcasts of these events, unless noted as press release only, will be posted on the Company's website at www.perspectivetherapeutics.com.

20.04.2026

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs) as part of a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026. [212Pb]VMT-α-NET is potentially the first-in-class 212Pb-radiopharmaceutical therapy targeting SSTR2.

02.04.2026

Perspective Therapeutics to Participate in Upcoming Investor Conferences

SEATTLE, April 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences:

17.03.2026

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

SEATTLE, March 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company's [212Pb]VMT-α-NET program have been accepted as a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026 taking place from April 17 to 22, 2026 in San Diego, CA as detailed below. AACR has announced that it will release further details for clinical trial abstracts for the conference on April 17, 2026.

16.03.2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

SEATTLE, March 16, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today provided a business update and announced full year results for the year ended December 31, 2025.

17.02.2026

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that it will report its full year 2025 financial results and provide a business update on Monday, March 16, 2025 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Видео

No Data

There is no data to display

Пресс-релизы

24.04.2026

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

20.04.2026

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

17.03.2026

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

16.03.2026

Perspective Therapeutics, Inc. (CATX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Search stocks

Perspective Therapeutics, Inc. (CATX)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Perspective Therapeutics, Inc. (CATX)

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics: Decent Prospect In Radiopharmaceuticals Field

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics to Participate in Upcoming Investor Conferences

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results

Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results

Видео

No Data

Пресс-релизы

Perspective Therapeutics to Provide Several Upcoming Corporate Updates

Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the AACR Annual Meeting 2026

Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2025 Results